Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

Idiopathic multicentric Castleman disease (iMCD) is a rare heterogeneous disorder involving multicentric lymphadenopathy, systemic inflammation, and cytokine-driven organ dysfunction. Despite the approval of siltuximab, a monoclonal antibody against interleukin-6, for the treatment of iMCD, it is no...

Descripción completa

Detalles Bibliográficos
Autores principales: van Rhee, Frits, Rosenthal, Adam, Kanhai, Karan, Martin, Rabecka, Nishimura, Katherine, Hoering, Antje, Fajgenbaum, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631655/
https://www.ncbi.nlm.nih.gov/pubmed/35793409
http://dx.doi.org/10.1182/bloodadvances.2022007112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631655/
https://www.ncbi.nlm.nih.gov/pubmed/35793409
http://dx.doi.org/10.1182/bloodadvances.2022007112

Ejemplares similares